Marker Therapeutics, Inc.

Monthly Archives: August 2017

TapImmune’s (TPIV) CEO Glynn Wilson on Q2 2017 Results – Earnings Call Transcript

Second Quarterly Call Earnings Call Transcript
Read More

TapImmune Provides Second Quarter 2017 Corporate and Clinical Update

Today TapImmune provides its business update for the second quarter 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.
Read More

TapImmune to Provide Second Quarter 2017 Business Update Conference Call and Webcast

TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the second quarter 2017.
Read More

Trial of Vaccine to Prevent Ovarian Cancer Recurrence Expands to Advanced-Stage Patients

TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
Read More

TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments

TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.
Read More